Posted by Hugo Ottolenghi
October 11th, 2009
The Web has erupted with news, opinion and practical guidance on the new FTC rules that apply to disclosures on blogger freebies. As a public service, NutriSupLaw offers a sampling of the best of initial analysis.
Posted by Hugo Ottolenghi
October 4th, 2009
Despite the recession, nutritional supplement companies remain popular with consumers and Wall Street. A $35 million merger and $132 million IPO are the latest examples of industry’s financial health.
Posted by Hugo Ottolenghi
September 27th, 2009
How closely can nutritional supplement companies connect with the fast-moving world of social media? The FDA will address these questions at a hearing Nov. 12-13 in Washington. The agency is soliciting comments in the Federal Register.
Posted by Hugo Ottolenghi
August 31st, 2009
This is a tale of two types of weight-loss products and how the Food and Drug Administration had different responses to similar problems with them. The separate, but not equivalent treatment raises questions about how the FDA operates.
Posted by Hugo Ottolenghi
August 23rd, 2009
GUEST POST by Jennifer Diaz The United States Food and Drug Administration (FDA) has authority to put an importer, manufacturer, shipper, grower, geographic area of a country, or an entire country on a “detention without physical examination” (DWPE) list (a/k/a the FDA’s ‘Black List’). To check if a company you are doing business with is [...]
Posted by Hugo Ottolenghi
August 19th, 2009
Placebos seem to make a difference in research and clinical practice. For that reason, testimonials and open-label trial results should never be provided as sole evidence of efficacy when a product marketing campaign is challenged by a regulatory authority.